NEW YORK, June 7, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Wall Street Reports announced new research reports highlighting Life Technologies Corporation (NASDAQ: LIFE), PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), Genomic Health, Inc. (NASDAQ: GHDX), and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Life Technologies Corporation Research Report
On May 23, 2013, Life Technologies Corporation (Life Technologies) announced the introduction of GeneArt Strings DNA Fragments, a cost-effective addition to the Company's custom gene synthesis services. GeneArt Strings are custom-ordered double-stranded segments of DNA that can be up to one kilobase (1,000 base pairs) in length. They offer the advantages of synthetic DNA along with quick processing times and five to seven business day delivery. "GeneArt Strings DNA Fragments constitute a cost-effective option for researchers who seek to reduce their work time and do not need to order genes cloned to a vector," said Nathan Wood, General Manager and Vice President of Synthetic Biology for Life Technologies. GeneArt products, including GeneArt Strings DNA Fragments are for research use only and not intended for diagnostic use. The Full Research Report on Life Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/d9de_LIFE]
PerkinElmer, Inc. Research Report
On June 4, 2013, PerkinElmer, Inc. (PerkinElmer) launched the ChemDraw and Chem3D apps, the new chemical structure drawing and visualization apps, for the iPad. The ChemDraw and Chem3D apps also feature PerkinElmer's Flick-to-Share technology which allows scientists to share critical information and inspire innovation in real-time, both in and out of the laboratory. "The launch of ChemDraw and Chem3D technology in a mobile form is a major milestone in the field of scientific computing," said Michael Stapleton, Vice President and General Manager of Informatics at PerkinElmer. "As the global leader in chemical drawing, we can now provide all chemists - from research scientists to high school students - with cost-effective, portable, and accessible applications that capture and share their moments of inspiration." The ChemDraw and Chem3D apps are the first of a series of mobile apps that the Company is developing to innovate on its leading electronic laboratory notebook (ELN) and scientific instrument franchises. The Full Research Report on PerkinElmer, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2d16_PKI]
PAREXEL International Corporation Research Report
On May 30, 2013, PAREXEL International Corporation (PAREXEL) announced that the Company ranked fifth in the Boston Globe's 25th annual "Globe 100" list of best performing public companies in Massachusetts. "This recognition not only demonstrates that our services are helping biopharmaceutical organizations transform drug development, but also reflects our enduring commitment to being a leading and innovative Massachusetts-based organization," said Josef von Rickenbach, Chairman and CEO of PAREXEL. The Company reported that it has an extensive track record of driving innovation in the biopharmaceutical services industry. "As it always has, the Globe 100 list reflects the dynamic nature of business not only in Massachusetts but also the world," added Steve Syre, Boston Globe Business Columnist and Editor of the 2013 Globe 100 Magazine. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/037f_PRXL]
Genomic Health, Inc. Research Report
On May 31, 2013, Genomic Health, Inc. (Genomic Health) announced the results of 10 studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. New data included studies of the Oncotype DX RT-PCR-based breast, colon, and prostate cancer tests and a large next generation sequencing (NGS) study that reports novel methods for detection of gene fusions to enhance the understanding of breast cancer tumor biology for future clinical developments. "Through continued research in breast, colon, and prostate cancers, and our next generation sequencing program, we continue to lead the way in how to translate vast amounts of genomic data into actionable information to improve health outcomes by eliminating 'one-size-fits-all' treatment in cancer," said Steven Shak, M.D., Chief Medical Officer at Genomic Health. "The new Oncotype DX research reflects our commitment to expanding our understanding of the biology of cancer and clinical utility of our tests for cancer patients throughout the course of their disease." The Full Research Report on Genomic Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/de5c_GHDX]
Bio-Reference Laboratories, Inc. Research Report
On May 30, 2013, Bio-Reference Laboratories, Inc. (Bio-Reference) announced that it plans to release its Q2 FY 2013 earnings results before the markets open for trading on June 6, 2013, followed by a conference call at 10:30 a.m. EDT. The call will be hosted by Marc D. Grodman, M.D., President and CEO, Bio-Reference. The Company released its Q1 FY 2013 results in February 2013, with revenues of $161.3 million, representing a 16.2% YoY growth. "We reaffirm our guidance for our current fiscal year as announced in our Q4FY12 earnings call. We remain focused on being the technology leader, the marketing leader, as well as the service leader in a service-dominated industry," said Marc D. Grodman. The Full Research Report on Bio-Reference Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/1a5c_BRLI]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
|SOURCE Wall Street Reports|
Copyright©2012 PR Newswire.
All rights reserved